T he main complications of portal venous thrombosis are intestinal ischemia and chronic portal hypertension. Intestinal ischemia occurs when thrombosis extends to the mesenteric venules. Portal hypertension develops when there is no repermeation of the portal vein. Recurrent gastrointestinal bleeding caused by portal hypertension has been reported to cause death in 5% 20% of patients in retrospective series including patients seen before 1980,1-5 but recent progress in management may have improved the outcome. In 1985, it was recognized that in many cases portal vein thrombosis was a complication of an underlying prothrombotic state) , 4, This finding led to the suggestion that long-term anticoagulation might prevent both extension of thrombosis in the splanchnic veins and thrombosis in other deep veins. 4,7,8,1°,22,35 Severe recurrence of gastrointestinal bleeding during anticoagulant therapy for portal vein thrombosis seems to be rare, 19 but the risk of it has not been evaluated precisely.
The aim of this multivariate retrospective analysis of a cohort of adult patients with noncancerous and noncirrhotic portal venous thrombosis was to assess (1) current outcome and (2) predictors of gastrointestinal bleeding and thrombotic events, with close attention to underlying prothrombotic states and to the administration of anticoagulant therapy.
Patients and Methods

Patients
All patients seen between 1983 and 1998 were enrolled if (1) they had been followed up at our institution; (2) portal venous thrombosis (endoluminal material and absence of flow in the portal vein or cavernous transformation of the vein) had been documented; (3) ongoing cancer had been excluded using all appropriate imaging and endoscopic procedures; (4) any kind of intrahepatic portal hypertension, including cirrhosis, had been excluded by normal liver function test results and normal aspect of the liver at imaging or normal aspect at liver biopsy; (5) obstruction of the hepatic veins had been ruled out using imaging procedures and liver biopsy, as appropriate; and (6) age was above 15 years.
Information on the use of anticoagulant agents was retrieved from the patients' chart. We included patients who were not treated with anticoagulant agents and those who were treated with unfractionated heparin, low-molecular-weight heparin, coumarin, or phenyl-indane-dione derivatives. Anticoagulant therapy has been considered for all patients seen since 1985. The potential risks and benefits of long-term administration of anticoagulant agents are explained to patients before their fully informed consent and that of their general practitioners is obtained. Patients were instructed not to use estrogens or nonsteroidal anti-inflammatory agents. Patients were removed from the study when they received antiplatelet agents, if any.
Data Analysis
Time of entry into the study was defined as the date of the imaging studies showing portal venous thrombosis. The end of follow-up was the date of latest news or the date of initiation of treatment with antiplatelet agents, if any. The date of point was February 1999. In the assessment of the risk of bleeding, patients were censored at the date of portocaval shunt construction, if any (i.e., date of the end of follow-up without bleeding).
The following data were analyzed: (1) incidence of gastrointestinal bleeding; (2) severity of gastrointestinal bleeding (duration of hospital stay, blood hemoglobin level on admission, volume of red cell concentrates transfused); (3) predictors of bleeding; (4) incidence of new thrombotic events, defined as thrombosis arising outside the portal venous system as well as recurrent thrombosis in the portal venous system manifested by mesenteric or splenic venous infarction; (5) predictors of new thrombotic events; and (6) incidence of recurrent thrombotic events in the portal venous system manifested by ruesenteric or splenic venous infarction.
As predictors of bleeding, we evaluated the following 6 variables: (1) age at the time of diagnosis of portal venous thrombosis; (2) sex; (3) initial manifestation of portal venous thrombosis as gastrointestinal bleeding; (4) prophylaxis for gastrointestinal bleeding in relation to the size of gastroesophageal varices as assessed at the time of diagnosis of portal vein thrombosis according to the following classification: grade 1, varices flattened by insufflation; grade 2, varices not flattened by insufflation, separated by healthy mucosal intervals; grade 3, confluence of varices not flattened by insufflation; grade 4, grade 3 with red marks36.3V; (5) anticoagulant therapy; and (6) stage of portal vein thrombosis (recent or old) at the time of diagnosis. Prophylaxis in relation to the size of gastroesophageal varices was classified into 3 categories: varices grade 0 or 1 and no prophylaxis; varices grade -->2 and adequate prophylactic measures; and varices grade -->2 and absent or inadequate prophylactic measures. Primary prophylaxis was considered adequate when patients with gastroesophageal varices grade -->2 were given ~-adrenergic blocking agents to achieve a 20% decrease in heart rate. Secondary prophylaxis was considered adequate when patients not receiving [3-adrenergic blocking agents before bleeding were then given this therapy. Secondary prophylaxis was also considered adequate in patients treated with endoscopic therapy to achieve eradication of esogastric varices whether or not they were undergoing [3- 
Statistical Methods
Statistical analysis was performed using the Student t test for comparison of quantitative data and Cox proportional hazard model for univariate and multivariate analysis of predictors for bleeding-free survival or survival without thrombotic events. An additional analysis of predictors for bleeding and thrombosis was performed taking into account multiple events from the same patient by fitting the Andersen-Gill multiplicative hazard model. 4°
Anticoagulant therapy and prophylaxis for gastrointestinal bleeding were treated as time-dependent variables. Multivariate survival analyses were stratified by date of diagnosis by choosing the median date (January 1, 1992) as a boundary. The binomial exact method was used to estimate the confidence interval of the incidence rate. Analyses were performed using SAS software (SAS Institute Inc., Cary, NC).
Results
Overall Characteristics of the Cohort
One hundred thirty-six patients were enrolled (74 men and 62 women). The median age at diagnosis of portal venous thrombosis was 43 years (range, 15-74 years). Initial manifestations were as follows: abdominal pain (n = 67), gastrointestinal bleeding related to portal hypertension (n = 24), mesenteric venous infarction (n = 7), ascites (n = 4), no clinical manifestations (i.e., fortuitous diagnosis; n = 10), and other clinical manifestations (n = 14). Portal venous thrombosis was demonstrated by means of duplex Doppler ultrasonography in 112 patients, computed tomographic scanning in 72, arteriography in 45, endosonography in 18, magnetic nuclear resonance in 8, and laparotomy in 3. The information on the cause of portal vein thrombosis is given in The median duration of follow-up was 46 months (range, 1-443 months). Fifty-two patients had not received anticoagulant therapy; 54 had received anticoagulant therapy during the entire follow-up, and 30 had received anticoagulant therapy only during a part of it. The last patients stopped taking anticoagulant agents either because they or their general practitioners decided to discontinue the therapy or because there was complete repermeation of the portal vein in the absence of underlying prothrombotic disorders, as reported previously. 38 Cumulative follow-up with and without anticoagulation was 309 and 382 patient-years, respectively. During oral anticoagulant therapy, the mean prothrombin level was 32.4% and mean international normalized ratio was 2.41.
Bleeding Events
In the analysis of bleeding events, 7 patients were removed from the study when they were given antiplatelet agents and 5 patients at the time of surgery for portal hypertension (splenorenal shunt in 2, mesocaval shunt in 2, and azygoportal deconnection in 1). Ten patients died. Thus, at the end of follow-up, 114 patients remained at risk of bleeding. Overall, 108 episodes of gastrointestinal bleeding occurred in 48 patients. Twenty-four bleeds showed portal vein thrombosis. During 673 patientyears of cumulative follow-up, 84 bleeding episodes occurred in 42 patients. Twenty patients bled once, 11 patients bled twice, and 17 patients bled 3-7 times. The incidence rate of first bleeding was 35% (48/136) and that of recurrent bleeding was 58% (28/48). The origin of gastrointestinal bleeding was gastroesophageal varices (n = 94), duodenal varices (n = 6), hypertension gastropathy (n = 3), sequels of endoscopic treatment for gastroesophageal varices (n = 3), gastric ulcer (n = 1), and ruptured spleen (n = 1). The global incidence of gastrointestinal bleeding was 12.5 (95% CI, 10-15) per 100 patient-years. The incidence rate of gastrointestinal bleeding was 16.0 (95% CI, 8.8-23.2) per 100 patientyears during the first year after diagnosis of portal vein thrombosis, 13.8 (95% CI, 6.3-21.3) per 100 patientyears during the second year, and 12.8 (95% CI, 4.9-20.7) per 100 patient-years during the third year. As shown in Table 2 , of the 6 variables assessed as predictors for bleeding-free survival, initial manifestation as gastrointestinal bleeding was of borderline statistical significance (P = 0.07) and varices grade -->2 with absent or inadequate prophylactic measures had independent prognostic value. Compared with patients with absent or small varices, the risk of gastrointestinal bleeding was not significantly increased for patients with varices grade ->2 in whom adequate prophylactic measures were carried out ( Table 2 ). As shown in Tables 2 and 3 , neither univariate nor multivariate analyses showed any significant association between anticoagulant therapy and the risk or severity of gastrointestinal bleeding. In the analysis taking into account multiple events, only varices grade ->2 had independent value for predicting bleeding (relative risk [RR], 4.4 and 4.1 with and without adequate prophylactic measures, respectively; P = 0.002 each). Anticoagulant therapy did not increase the risk of bleeding (RR, 0.9; P = 0.9).
Thrombotic Events
In the analysis of thrombotic events, 7 patients were removed from the study when they were given antiplatelet agents and 10 patients died. Thus, at the end of follow-up, 119 patients remained at risk of thrombosis. Thirty-eight thrombotic events occurred in 26 patients during 691 patient-years of cumulative follow-up. The sites of thrombosis were as follows: deep vein thrombosis in the lower limb (n = 18), pulmonary embolism (n = 5), myocardial infarction (n = 1), ischemic stroke (n = 2), lower limb arterial thrombosis (n = 2), hepatic infarction (n = 1), mesenteric venous infarction (n = 8), and splenic venous infarction (n = 1). The incidence rate of all types of thrombotic events was 5.5 (95% CI, 3.8-7.2) per t00 patient-years. The incidence rate of all types of thrombotic events was 3.4 (95% CI, 0.1-6.7) per 100 patient-years during the first year after the diagnosis of portal vein thrombosis, 6.4 (95% CI, 1.3-11.5) per 100 patient-years during the second year, and 7.7 (95% CI, 1.6-13.8) per 100 patient-years during the third year. As shown in Table 4 , of the 6 variables assessed as predictors of survival without new thrombotic events, only documented prothrombotic state (P = 0.004) and anticoagulant therapy (P = 0.06) had independent prognostic value. The analysis taking into account multiple events likewise identified underlying prothrombotic state (RR, 5.3; P = 0.0002) and absence of anticoagulant therapy (RR, 0.39; P = 0.02) as independent predictors of bleeding. Nine patients had recurrent thrombotic events in the portal venous system: mesenteric venous infarction in 8 and splenic venous infarction in 1. In the whole population, the incidence of recurrent thrombotic events in the portal venous system was 0.64 and 1.87 per 100 patient-years in patients with and without anticoagulant therapy, respectively (RR, 2.9; 95% CI, 0.6-14). In patients with a documented prothrombotic state, the incidence of recurrent thrombotic events in the portal venous system was 0.82 and 5.19 per 100 patient-years in patients with and without anticoagulant therapy, respectively (RR, 6.3; 95% CI, 1.3-30.4; P = 0.01). Only 2 episodes of mesenteric venous infarction occurred on anticoagulant therapy. These 2 episodes took place at a time when insufficient anticoagulation was documented. All patients with recurrent thrombotic events in the portal venous system had documented prothrombotic states.
Mortality
Ten patients died during a median follow-up of 46 months (95% CI, 32-54 months). Mean age at death was 62 years (median, 58 years; range, 41-77 years). The mean age at diagnosis of the patients who died was 54 years (SD, 11.5 years), compared with a mean age at diagnosis of 42.2 years (SD, 13.5 years) in the patients who survived (P = 0.01). In 4 cases, death was directly related to portal venous thrombosis: gastrointestinal bleeding in 2 patients receiving no anticoagulant therapy and intestinal infarction in 2 patients receiving no anticoagulant therapy. The 6 other deaths were not related to portal vein thrombosis or its treatments.
Discussion
The natural history of portal vein thrombosis is unknown because in all reported cohorts of patients, some form of therapy has been administered for portal hypertension or thrombophilia. The rarity of portal vein thrombosis has not allowed controlled therapeutic trials to be conducted. Therefore, the influence of the various medical or surgical interventions remains ill-known. With these limitations as a background, the present survey has allowed re-evaluation of the outcome of portal vein thrombosis. Compared with previous studies, the strengths of this survey are (1) greater homogeneity through the exclusion of children and of patients with cancer or cirrhosis, whose prognosis is affected by factors not relevant to portal venous obstruction per se; (2) consideration, for the first time, of the underlying prothrombotic state (in terms of both risk of recurrent thrombosis and need for anticoagulant therapy); (3) the large number of patients; (4) multivariate analysis, which permitted adjustment for potential confounding factors; and (5) the recent study period, which allowed assessment of the influence of modern therapy for portal hypertension and prothrombotic states. Several biases might have been introduced into this retrospective study. Selection biases were kept minimal by enrolling all the patients seen and treated at our institution. The long study period (15 years) has probably been associated with a change in the profile from the patients seen early in this period to those seen later. Indeed, recent data show that patients seen recently were more likely to have portal vein thrombosis diagnosed at a recent stage. 38 However, this factor was taken into account in the multivariate analysis. Treatment biases also must be considered. Treatment variability in this survey resulted from 2 factors: historical variation in proposition for treatment (anticoagulation in more recent years), patients' acceptance of therapies that had not been rigorously evaluated yet. It is likely that patients who had suffered from extrasplanchnic thrombosis or from recurrent splanchnic thrombosis were more likely to accept anticoagulant therapy than patients with a history of gastrointestinal bleeding. Both factors were carefully taken into account in the multivariate analysis. Moreover, in patients enrolled in the early part of our experience and initially not considered for anticoagulation therapy but later undergoing it, both periods on anticoagulation therapy and periods without it were taken into account.
The characteristics and results of the main reported studies addressing mortality in patients with portal vein thrombosis are shown in Table 5 . Their diverse characteristics make comparison with our own findings difficult. In the present survey, mortality was low. Most importantly, portal vein thrombosis or the underlying thrombophilia accounted for only 4 of the 10 deaths. Expectedly, age appeared to be a main determinant of prognosis. Recurrent or extensive thrombosis was responsible for as many deaths as gastrointestinal bleeding.
The importance of thrombosis in the outcome had not been recognized previously. Compared with previously reported cohorts, the incidence of gastrointestinal bleeding has remained the most common complication of portal venous thrombosis. The incidence rate was 12.5 per 100 patient-years. The size of gastroesophageal varices and, to a lesser degree, initial presentation with gastrointestinal bleeding were independent predictors for bleeding in patients with portal vein thrombosis, just as they are in patients with cirrhosis. 41 Our strategy for preventing first or recurrent bleeding was derived from that validated in cirrhotic patients with moderate-sized or large varices: [3-adrenergic blocking agents in the first line and endoscopic therapy in the second line. 42 The present findings indicate that this strategy is also able to decrease the risk of bleeding in patients with portal vein thrombosis. Our data do not permit formal comparison of this primarily nonsurgical strategy with surgery because the latter was performed in only 5 patients. However, our strategy resulted in only 1.5% mortality from gastrointestinal bleeding, which compares most favorably with the results of previously reported cohorts having a larger recourse to surgery (Table 5 ). This observation is more interesting because many of our patients received anticoagulant therapy. In fact, a major finding in this study was that anticoagulant therapy did not increase the risk or severity of bleeding. Actually, there was a decreased risk of bleeding, although this decrease was not statistically significant. Furthermore, there was no death from bleeding in patients receiving anticoagulant therapy. Theoretically, a possible favorable effect of anticoagulant therapy on the risk of bleeding might be expected from preventing extension of thrombosis in the portal venous system as well as in portoportal or portosystemic collaterals, thereby preventing increase in portal pressure.
In the present cohort, thrombotic events proved to be as clinically significant as gastrointestinal bleeding. The incidence rate of thrombotic events (5.5 per 100 patientyears) was almost half of that of bleeding (12.5 per 100 patient-years). In patients with a recognized prothrombotic state, the incidence rate of thrombotic events (8.4 per 100 patient-years) was two thirds of the overall incidence rate of gastrointestinal bleeding. Furthermore, as many patients died of thrombosis as died of bleeding, despite a lower incidence of the former. In other words, the lethality of thrombosis was higher than that of gastrointestinal bleeding. This issue had not been addressed in previous surveys of cavernous transformation of the portal vein. It had been suggested that patients with underlying thrombophilic conditions would be at particular risk of extension of thrombosis in the portal and mesenteric venous territory. 2°,43 The present findings support this view because an extension of thrombosis in the portal venous system was encountered only in patients with demonstrated underlying thrombophilic conditions.
A major observation in this survey was that anticoagulant therapy reduced the risk of thrombotic event by two thirds. The reduction affected mainly recurrence or extension within the portal venous system. In fact, only 2 patients had recurrent mesenteric vein thrombosis while they were undergoing anticoagulant therapy, albeit at an insufficient dose. Therefore, the present survey strongly indicates a favorable benefit-risk ratio for anticoagulant therapy in patients with portal vein thrombosis because of the absence of aggravation of the risk or severity of bleeding on the one hand and because of reduction in the risk of new thrombotic events on the other. However, generalization of the findings from this retrospective study merits caution. Results of surveys from other centers are needed to corroborate our findings in waiting for the results of controlled trials that will be difficult to perform. At present, based on our results, it seems that some patients could find particular benefit from anticoagulant therapy: those patients with demonstrated prothrombotic states, with absent or small varices that never bled, and without predictable bleeding sites outside the gastrointestinal tract during anticoagulant therapy. Anticoagulant therapy should also be considered in patients with prothrombotic states and esophageal varices that never bled if adequate prophylaxis for bleeding from portal hypertension has been instituted. In other cases, indications for anticoagulant therapy appears less clear, and anticoagulant therapy may still be beneficial, although marginal.
In summary, we have showed that the current outcome of portal venous thrombosis is good; mortality is strongly related to advanced age; recurrent thrombosis is almost as frequent as recurrent bleeding in patients with underlying prothrombotic states; and oral anticoagulation has a favorable benefit-risk ratio, particularly in patients with underlying prothrombotic disorders.
